Download Free Tumor Markers In Cancer Control Book in PDF and EPUB Free Download. You can read online Tumor Markers In Cancer Control and write the review.

Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers Provides immediately actionable information – and hopefully also inspiration – to move discovery and clinical application forward Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers
This book presents the latest research on advances in genetics, molecular medicine, biotechnologies, and behavioural sciences that have an impact on primary, secondary and tertiary cancer prevention including: (a) Basic mechanisms of neoplastic diseases leading to the identification of molecular pathways that can be employed as targets for cancer prevention; (b) Descriptive, analytical, and molecular epidemiology with emphasis on developing biomarkers of cancer risk assessment and response to cancer prevention; (c) Laboratory and clinical procedures for prognostic evaluation of malignant tumour transformation, progression and response to treatment with cancer preventive agents; (d) Discoveries of natural substances and synthetic agents that have promising cancer preventive potential and elucidating their mechanistic action; (e) Development and assessment of cancer preventive approaches that have potential for being translated into the clinic; (f) Cancer prevention pre-clinical studies and clinical trials; (g) Patient management and education, management of curable lesions, education and lifestyle modification and the role of behavioural factors in cancer etiology and prevention.
Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.
This volume contains the majority of the invited keynote lectures presented by experts at the Third International Conference on Controversies in Tumor Prevention and Genetics on 12-14 February 2004 in St.Gallen, Switzerland. Together, they reveal the latest findings in oncogenetics and its relations to recent and future developments in primary and secondary tumor prevention, especially in breast, colon and lung cancer. All contributions are written and have been critically reviewed by internationally recognised leaders in the field.